The key role of the amino sugar pathway for T. gondii viability, and the predicted significance of GPI anchors and GlcNAc-containing glycoconjugates across T. gondii’s life cycle [7,22], underscore the potential of GNA1 as a versatile multistage therapeutic target in toxoplasmosis that could be exploited for selective parasite inhibition. This evidence concerns the gene GNPNAT1 and toxoplasmosis.